A Composite Endpoint for Acceptability Evaluation of Oral Drug Formulations in the Pediatric Population
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2168-4804
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
A Composite Endpoint for Acceptability Evaluation of Oral Drug Formulations in the Pediatric Population ; day:26 ; month:4 ; year:2022 ; pages:1-7
Therapeutic innovation & regulatory science ; (26.4.2022), 1-7
- Creator
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s43441-022-00406-z
- URN
-
urn:nbn:de:101:1-2022070908142392939118
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
07.01.1970, 12:00 AM CET
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Wargenau, Manfred
- Reidemeister, Sibylle
- Klingmann, Ingrid
- Klingmann, Viviane
- SpringerLink (Online service)
Other Objects (12)
Young patients’ involvement in a composite endpoint method development on acceptability for paediatric oral dosage forms
Acceptability of placebo multiparticulate formulations in children and adults
A patient-centered composite endpoint weighting technique for orthopaedic trauma research
Efficacy, safety, tolerability and acceptability of two pediatric formulations of artesunate-mefloquine in African children with acute uncomplicated Plasmodium falciparum malaria
Acceptability, Swallowability, and Palatability of Three Oral Placebo Formulations in Young Children
Skin endpoint titration
The empirical estimate of the survival and variance using a weighted composite endpoint
Endpoint relations for baryons
Performance Evaluation of Montelukast Pediatric Formulations: Part II — a PBPK Modelling Approach
The feasibility and validity of a preference-weighted composite endpoint to establish value in geriatric care
Informative noncompliance in endpoint trials
The endpoint of partial deconfinement
Young patients’ involvement in a composite endpoint method development on acceptability for paediatric oral dosage forms
Acceptability of placebo multiparticulate formulations in children and adults
A patient-centered composite endpoint weighting technique for orthopaedic trauma research
Efficacy, safety, tolerability and acceptability of two pediatric formulations of artesunate-mefloquine in African children with acute uncomplicated Plasmodium falciparum malaria
Acceptability, Swallowability, and Palatability of Three Oral Placebo Formulations in Young Children
Skin endpoint titration
The empirical estimate of the survival and variance using a weighted composite endpoint
Endpoint relations for baryons
Performance Evaluation of Montelukast Pediatric Formulations: Part II — a PBPK Modelling Approach
The feasibility and validity of a preference-weighted composite endpoint to establish value in geriatric care
Informative noncompliance in endpoint trials
The endpoint of partial deconfinement
Young patients’ involvement in a composite endpoint method development on acceptability for paediatric oral dosage forms
Acceptability of placebo multiparticulate formulations in children and adults
A patient-centered composite endpoint weighting technique for orthopaedic trauma research
Efficacy, safety, tolerability and acceptability of two pediatric formulations of artesunate-mefloquine in African children with acute uncomplicated Plasmodium falciparum malaria
Acceptability, Swallowability, and Palatability of Three Oral Placebo Formulations in Young Children
Skin endpoint titration
The empirical estimate of the survival and variance using a weighted composite endpoint
Endpoint relations for baryons
Performance Evaluation of Montelukast Pediatric Formulations: Part II — a PBPK Modelling Approach
The feasibility and validity of a preference-weighted composite endpoint to establish value in geriatric care
Informative noncompliance in endpoint trials